Fig. 2. Knockdown or overexpression of ASF1B in cervical cancer cells.
a A total of 1 × 105 CaSki or HeLa cells were seeded in each well of a 6-well plate, and the recombinant plasmid ASF1B-shRNA was transfected into cells with Lipofectamine®2000. The cells were incubated in complete Opti-MEM medium containing G418 for 30 days to select positive cells. A limited dilution strategy was performed, and the positive cell clones were selected. b ASF1B protein expression in stable ASF1B-shRNA-cells. Western blot detecting lower ASF1B protein levels in stable ASF1B-shRNA-CaSki or ASF1B-shRNA-HeLa cells than those in control cells. c Quantification of the results in (b). Data are mean ± SEM, n = 3, and two-tailed unpaired Student’s t test was used. ***p < 0.001. d. Establishment of ASF1B overexpression in CaSki or HeLa cells with overexpression technology. pcDNA3.1-ASF1B was transfected into human CaSki and HeLa cells using Lipofectamine®2000. e Western blot results showed that observable ASF1B protein was detected in ASF1B-CaSki and HeLa cells relative to that in control cells. f Quantification of the results in (e). Data are mean ± SEM, n = 3, and two-tailed unpaired Student’s t test was used. ***p < 0.001.